Equities Analysts Offer Predictions for AUTL Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Autolus Therapeutics to a loss of $0.20 per share from $0.21, while maintaining a Buy rating and $10 price target.
• Autolus reported a quarterly loss of $0.15 per share, beating expectations for a $0.21 loss, and revenue of $45.69 million exceeded the $38.56 million consensus estimate.
• Despite the earnings and revenue beat and stronger AUCATZYL launch outlook, the company remains unprofitable, with a negative 238.66% net margin; analysts collectively rate the stock Moderate Buy with a $10 average target.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Investment analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for Autolus Therapeutics in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.20) for the quarter, up from their prior estimate of ($0.21). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Autolus Therapeutics' Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.21) EPS.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. The company had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative return on equity of 152.15% and a negative net margin of 238.66%.

Several other analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 31st. Wall Street Zen raised Autolus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.00.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $2.12 on Thursday. The firm's 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.56. Autolus Therapeutics has a one year low of $1.17 and a one year high of $2.43. The company has a market cap of $564.26 million, a PE ratio of -2.00 and a beta of 2.07.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Marex Group plc bought a new stake in Autolus Therapeutics during the second quarter valued at $28,000. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics in the 4th quarter worth about $28,000. GAMMA Investing LLC lifted its stake in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after purchasing an additional 8,309 shares during the period. SmartHarvest Portfolios LLC acquired a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $43,000. Finally, Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $37,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics News Roundup

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported second-quarter revenue of $45.69 million, above the $38.56 million analyst consensus, while its adjusted loss of $0.15 per share was narrower than the expected $0.21 loss. Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
• Positive Sentiment: Management raised its AUCATZYL outlook, signaling stronger-than-anticipated commercial launch momentum. The updated guidance and progress in expanding adoption are the main catalysts supporting investor interest in AUTL. Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
• Positive Sentiment: The earnings presentation and conference call highlighted the company’s commercial and operational progress, reinforcing the view that AUCATZYL could become an important source of future revenue. Autolus Therapeutics plc 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the data shows no measurable short position and includes an apparent “NaN” change, it provides little useful insight into current trading pressure.
• Negative Sentiment: Despite the quarterly beat, Autolus remains unprofitable, reporting a $0.15 per-share loss, negative return on equity, and a deeply negative net margin. Continued cash needs and execution risks surrounding the AUCATZYL launch may be limiting enthusiasm and contributing to the recent decline.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source